Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Biotechnology

Healthcare
$1.72 -2.64%

-$0.05 today

Market cap
$765.80M
Beta
1.07
P/E (TTM)
-30.5
EPS (TTM)
-$0.07
52W Low $0.71High $2.53

Volume 2.02M

Average 2.48M

LXRX Total Debt

Short-term and long-term borrowings combined.

Lexicon Pharmaceuticals, Inc.NASDAQ: LXRX

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt falls 45.7% from a year ago

Total debt stood at $57.71M at the end of Q1 FY2026, down 45.7% from a year earlier and down 7.3% from the prior quarter. Over 3 fiscal years it compounded at +4.0% a year.

Context

  • Total debt amounted to 21.5% of total assets at the end of Q1 FY2026, down 14.2 pp from a year earlier.
  • Total debt increased in 2 of the last 3 fiscal years.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -45.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$57.71M-7.3% QoQ
Last fiscal yearDec 2025
$62.24M-42.6% YoY
Year agoMar 2025
$106.26M-45.7% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-45.7%——
1 year-42.6%——
3-year CAGR+4.0%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
62.24M USD
Year-over-year change
-42.6%
4-year CAGR
+128.6%

Total Debt vs competitors

How LXRX compares with its peers on the latest reported figures

  • LXRX's Mar 2026 total debt of $57.71M is the 5th highest of the 11 companies compared; the peer median is $24.51M.
  • Its year-over-year change of -45.7% is the 9th highest of 11, against a peer median of -29.0%.
  • Total debt amounts to 21.5% of total assets for LXRX, versus a peer median of 4.9%.
LXRX Competitors Peer median
Total Debt for LXRX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IONSIonis Pharmaceuticals, Inc.Sep 2026$2.15B +44.5%+24.1%73.9%
PTCTPTC Therapeutics, Inc.Jun 2026$696.47M +79.4%+22.8%21.4%
MNKDMannKind CorporationMar 2026$436.67M +824.2%+18.0%58.7%
BCRXBioCryst Pharmaceuticals, Inc.Jun 2026$409.86M -41.7%-16.0%73.5%
LXRXLexicon Pharmaceuticals, Inc.Mar 2026$57.71M -45.7%+4.0%21.5%
RIGLRigel Pharmaceuticals, Inc.Mar 2026$45.72M -25.1%+8.7%9.1%
ORICORIC Pharmaceuticals, Inc.Mar 2026$3.3M +2.6%-1.5%0.8%
OVIDOvid Therapeutics Inc.Mar 2026$1.46M -89.9%-6.7%0.6%
TRVITrevi Therapeutics, Inc.Sep 2026$527K -36.0%-56.5%0.2%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$410K -56.3%-61.6%0.3%
DMACDiaMedica Therapeutics Inc.Mar 2026$212K -32.9%-20.0%0.4%
Peer median (excluding LXRX) $24.51M-29.0%-4.1%4.9%

Competitors are the stored peer set for LXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents64.07M46.35M22.47M66.66M34.33M
Short-term Investments22.68M92.01M147.56M171.3M61.9M
Net Receivables14K28K1.01M3.47M2.38M
Inventory00381K231K281K
Other Current Assets02.48M5.13M4.53M3M
Total Current Assets88.92M140.87M176.55M246.19M101.9M
Property, Plant & Equipment (Net)3.45M8.48M7.51M7.32M9.18M
Goodwill44.54M44.54M44.54M44.54M44.54M
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets0412K828K368K29.37M
Total Non-current Assets47.99M53.43M52.88M52.23M83.09M
Total Assets136.91M194.3M229.43M298.42M184.99M
Account Payables9.15M10.4M14.39M14.8M3.08M
Short-term Debt00006.24M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities5.71M3.66M9.59M14.71M5.13M
Total Current Liabilities22.12M23.17M31.55M45.25M20.87M
Long-term Debt048.58M99.51M100.3M49.41M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0000582K
Total Non-current Liabilities1.19M54M104.77M107.22M56.58M
Total Liabilities23.31M77.18M136.32M152.47M77.45M
Common Stock150K189K245K363K366K
Retained Earnings(1.49B)(1.59B)(1.77B)(1.97B)(2.02B)
Accumulated OCI(10K)(428K)31K119K30K
Other Stockholders Equity00000
Minority Interest00000
Total Equity113.6M117.12M93.11M145.95M107.54M
Total Debt2.28M55.29M106.06M108.4M62.24M
Net Debt(61.79M)8.95M83.6M41.74M27.91M

Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Intrinsic Alpha fair value

Locked

Current Price

$1.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.